Loading...
•
Sep 30, 2023
Trevena Q3 2023 Earnings Report
Reported promising proof-of-concept data for TRV045 studies and strengthened balance sheet with the receipt of the $15 million dollar R-Bridge tranche.
Key Takeaways
Trevena reported its financial results for the third quarter ended September 30, 2023. The company reported promising proof-of-concept data for its two TRV045 studies, including favorable safety and tolerability topline data, and strengthened its balance sheet with the receipt of the $15 million R-Bridge tranche.
Reported statistically significant topline TRV045 data from two proof-of-concept studies.
Reported favorable safety and tolerability data from TRV045 POC studies.
Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference.
Received $15 million tranche from ex-US royalty-based financing agreement in September.
Forward Guidance
Cash and cash equivalents were $35.0 million as of September 30, 2023, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the third quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...